Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
- 5 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Targeted Oncology
- Vol. 16 (2), 189-196
- https://doi.org/10.1007/s11523-020-00786-y
Abstract
Background Subgroup analysis of KEYNOTE-045 suggested that cigarette smoking had a positive impact on the effectiveness of pembrolizumab in patients with advanced urothelial carcinoma (UC), whereas studies on other cancers treated with immune checkpoint inhibitors reported inconsistent results. Objectives This study aimed to examine the association between smoking-related factors and the effectiveness of pembrolizumab in patients with metastatic UC. Patients and methods This multicenter retrospective study was conducted using data from 95 patients with metastatic UC treated with pembrolizumab. The primary outcomes were progression and all-cause mortality. Time-to-event outcomes were compared with smoking history and lifetime smoking exposure at treatment initiation. Survival curves were compared using the log-rank test, with hazard ratios (HRs) estimated from Cox regression models. Cubic spline regression analysis was used to depict event hazards. Results We identified 32 (34.7%) patients with heavy smoking exposure (≥ 25 pack-years). Moreover, 19 (20.0%), 36 (37.9%), and 40 (42.1%) patients were current, former, and never smokers, respectively. Multivariable models showed that heavy smoking exposure was significantly associated with lower risk of progression (HR 0.58; 95% confidence interval (CI) 0.35–0.97; P = 0.047) and all-cause mortality (HR 0.30; 95% CI 0.11–0.82; P = 0.019). Cubic spline regression analyses revealed a dose-effect relationship. No significant association was observed between smoking history alone and effectiveness of pembrolizumab. Conclusions Lifetime smoking exposure plays a significant role in the effectiveness of pembrolizumab in patients with metastatic UC.Keywords
This publication has 23 references indexed in Scilit:
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-AnalysisJournal of Thoracic Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisOncotarget, 2016
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Relaxing the Rule of Ten Events per Variable in Logistic and Cox RegressionAmerican Journal of Epidemiology, 2006
- Scoring System and Clinical Application of COPD Diagnostic QuestionnairesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- The impact of characteristics of cigarette smoking on urinary tract cancer riskCancer, 2000
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Cigarette smoking and cancers of the renal pelvis and ureter.1992